OOMA vs REGN · P/E 52, $468.2M cap vs P/E 14, rev $14.34B
Ooma Inc (OOMA) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Ooma Inc (OOMA) is a software - application company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
OOMA does not have a complete income-statement cache yet.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
OOMA currently screens at market cap $468.2M and trailing P/E 51.6. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the OOMA and REGN stock pages for the full models.
Not investment advice.